Cardiff Oncology, Inc.
CRDF- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001213037
In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.2M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Cardiff Oncology, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 91 | 2 | 67 | −22 |
| Shares | 16.5M | 35.2K | 8.93M | −7.56M (−45.9%) |
| Value | $41.0M | $87.0K | $19.6M | −$21.2M (−51.9%) |
2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held Cardiff Oncology, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Laurion Capital Management LP | 722,100 | $1.59M | 0.07% |
| Ergoteles LLC | 184,000 | $405.0K | 0.01% |
| Qube Research & Technologies Ltd | 33,038 | $73.0K | 0.00% |
| MYDA Advisors LLC | 30,000 | $66.0K | 0.03% |
| Dimensional Fund Advisors LP | 18,531 | $41.0K | 0.00% |
| LMR Partners LLP | 13,584 | $30.0K | 0.00% |
| Virtu Financial LLC | 12,563 | $28.0K | 0.00% |
| Eagle Bay Advisors LLC | 339 | $746 | 0.00% |
| Credit Suisse AG | 20 | $0 | 0.00% |
| TCI Wealth Advisors, Inc. | 100 | $0 | 0.00% |
Sold out (32)
Institutions that held Cardiff Oncology, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
Not filed for Q2 2022 yet (2)
Institutions that held Cardiff Oncology, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Parametric Portfolio Associates LLC | 30,601 | $76.0K |
| Amalgamated Financial Corp. | 4,585 | $11.0K |